 | | | | About one in 10 children had symptoms that remained after recovering from COVID-19, though that number dropped by more than half as the months passed, a Health Ministry survey showed on Monday. | | | | | | Drugstore chain Walgreens Boots Alliance's COVID-19 test registration system exposed data of potentially millions of people, including their phone numbers and email addresses, Recode reported on Monday. | | | | | | Abortion rights advocates on Monday urged the U.S. Supreme Court not to overturn the Roe v. Wade ruling that legalized abortion nationwide - a 1973 landmark imperiled in the legal fight over Mississippi's attempt to ban the procedure after 15 weeks of pregnancy. | | | | | | The U.S. Centers for Disease Control and Prevention on Monday warned against travel to Afghanistan, Albania, Serbia, Belize, Lithuania and four other destinations because of COVID-19 concerns. | | | | | | Purdue Pharma, the bankrupt maker of the OxyContin painkiller, on Monday obtained court approval to pay up to $7.1 million in incentive payments for five top executives if they meet certain goals, despite opposition from U.S. government lawyers. | | | | | | The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review. | | | | | | U.S. President Joe Biden's plan requiring more than 100 million Americans to get vaccinated against COVID-19 relies on a rarely used workplace rule with a history of being blocked in court, making it an inviting target for legal challenges by employers. | | | | | | The number of French patients in hospital with COVID-19 fell below 10,000 again for the first time since mid-August, health ministry data showed on Monday. | | | | | | The Philippines' capital region will shift to localised lockdowns and an alert level system starting Sept. 16 to prevent the spread of coronavirus while allowing more businesses to resume operations, the president's spokesperson said late on Monday. | | | | | | Drugmaker Merck & Co Inc said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end. | | | | | |
